BACKGROUND: One of the goals of the National HIV/AIDS Strategy (NHAS) is to increase the proportion of HIV-infected individuals linked to care within 3 months of diagnosis (early linkage) from 65% to 85%. Earlier access to care, and eventually, to treatment, increases life expectancy and quality of life for HIV-infected persons. However, longer treatment is also associated with higher costs, especially for antiretroviral drugs. We evaluated the cost effectiveness of achieving the NHAS goal and estimated the maximum cost that HIV programs could spend on linkage to care and remain cost effective. METHODS: We used the Progression and Transmission of HIV/AIDS model to estimate the effects on life measures and costs associated with increasing early linkage to care from 65% to 85%. We estimated an incremental cost-effectiveness ratio as the additional cost required to reach the target divided by the quality-adjusted life years (QALYs) gained and assumed that programs costing $100,000 or less per QALY gained are cost effective. RESULTS: Achieving the NHAS linkage-to-care goal increased life expectancy by 0.4 years and delayed the onset of AIDS by 1.2 years on average for every HIV-diagnosed person. Increasing early linkage to care cost an extra $62,200 per QALY gained, considering only benefits to index persons. The maximum that could be cost effectively spent on early linkage-to-care interventions was approximately $5100 per HIV-diagnosed person. CONCLUSIONS: Considerable investment can be cost effectively made to achieve the NHAS goal on early linkage to care.
BACKGROUND: One of the goals of the National HIV/AIDS Strategy (NHAS) is to increase the proportion of HIV-infected individuals linked to care within 3 months of diagnosis (early linkage) from 65% to 85%. Earlier access to care, and eventually, to treatment, increases life expectancy and quality of life for HIV-infectedpersons. However, longer treatment is also associated with higher costs, especially for antiretroviral drugs. We evaluated the cost effectiveness of achieving the NHAS goal and estimated the maximum cost that HIV programs could spend on linkage to care and remain cost effective. METHODS: We used the Progression and Transmission of HIV/AIDS model to estimate the effects on life measures and costs associated with increasing early linkage to care from 65% to 85%. We estimated an incremental cost-effectiveness ratio as the additional cost required to reach the target divided by the quality-adjusted life years (QALYs) gained and assumed that programs costing $100,000 or less per QALY gained are cost effective. RESULTS: Achieving the NHAS linkage-to-care goal increased life expectancy by 0.4 years and delayed the onset of AIDS by 1.2 years on average for every HIV-diagnosed person. Increasing early linkage to care cost an extra $62,200 per QALY gained, considering only benefits to index persons. The maximum that could be cost effectively spent on early linkage-to-care interventions was approximately $5100 per HIV-diagnosed person. CONCLUSIONS: Considerable investment can be cost effectively made to achieve the NHAS goal on early linkage to care.
Authors: Rochelle P Walensky; Paul E Sax; Yoriko M Nakamura; Milton C Weinstein; Pamela P Pei; Kenneth A Freedberg; A David Paltiel; Bruce R Schackman Journal: Ann Intern Med Date: 2013-01-15 Impact factor: 25.391
Authors: Catherine Maulsby; Kriti M Jain; Brian W Weir; Blessing Enobun; Melissa Werner; Morey Riordan; David R Holtgrave Journal: AIDS Behav Date: 2018-11
Authors: Bruce R Schackman; Lisa R Metsch; Grant N Colfax; Jared A Leff; Angela Wong; Callie A Scott; Daniel J Feaster; Lauren Gooden; Tim Matheson; Louise F Haynes; A David Paltiel; Rochelle P Walensky Journal: Drug Alcohol Depend Date: 2012-09-09 Impact factor: 4.492
Authors: Bruce R Schackman; John A Fleishman; Amanda E Su; Bethany K Berkowitz; Richard D Moore; Rochelle P Walensky; Jessica E Becker; Cindy Voss; A David Paltiel; Milton C Weinstein; Kenneth A Freedberg; Kelly A Gebo; Elena Losina Journal: Med Care Date: 2015-04 Impact factor: 2.983
Authors: Pamela P Pei; Milton C Weinstein; X Cynthia Li; Michael D Hughes; A David Paltiel; Taige Hou; Robert A Parker; Melanie R Gaynes; Paul E Sax; Kenneth A Freedberg; Bruce R Schackman; Rochelle P Walensky Journal: HIV Clin Trials Date: 2015-12-11
Authors: Dustin J Rabideau; Pamela P Pei; Rochelle P Walensky; Amy Zheng; Robert A Parker Journal: Med Decis Making Date: 2017-11-09 Impact factor: 2.583
Authors: Rochelle P Walensky; Tim Horn; Nicole C McCann; Kenneth A Freedberg; A David Paltiel Journal: Ann Intern Med Date: 2020-03-10 Impact factor: 25.391
Authors: Maunank Shah; Allison Perry; Kathryn Risher; Sunaina Kapoor; Jeremy Grey; Akshay Sharma; Eli S Rosenberg; Carlos Del Rio; Patrick Sullivan; David W Dowdy Journal: Lancet HIV Date: 2016-02-08 Impact factor: 12.767